earnings
confidence high
sentiment positive
materiality 0.80
GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance
GeneDx Holdings Corp.
2025-Q3 EPS reported
-$0.12
revenue$306,550,000
- Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).
- Adjusted gross margin expanded to 74% from 64%; adjusted net income $14.7M vs $2.0M.
- Raised FY2025 revenue guidance to $425-428M; exome/genome growth 53-55% YoY.
- Granted FDA Breakthrough Device Designation for ExomeDx and GenomeDx tests.